Corvus Pharmaceuticals, Inc. Debt Securities, Available-for-sale, Amortized Cost, Current
Corvus Pharmaceuticals, Inc. (CRVS) had Debt Securities, Available-for-sale, Amortized Cost, Current of $197.08 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Debt Securities, Available-for-Sale, Amortized Cost
us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent · last filed 2026-08-06
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost, Current $197.08M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost, Current $196.88M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost, Current $52.11M.
- 2024-12-31: Debt Securities, Available-for-sale, Amortized Cost, Current $43.14M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost, Current |
|---|---|
| 2026-06-30 | $197.08M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $196.88M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $52.11M 10-Q · filed 2026-08-06 |
| 2024-12-31 | $43.14M 10-K · filed 2026-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |